Non-Opioid Chronic Pain Therapy Exilby Secures German Authorization
Therapeutic innovation in chronic pain: VERTANICAL’s Exilby has shown superior pain reduction and better gastrointestinal tolerability than opioids in Phase 3 study.
Therapeutic innovation in chronic pain: VERTANICAL’s Exilby has shown superior pain reduction and better gastrointestinal tolerability than opioids in Phase 3 study.
The NMPA clearance allows Adcentrx to include China-based clinical centres in its ongoing Phase 1a/1b trial evaluating the ADC in patients with late-stage solid tumours, including prostate cancer.
The Hugo RAS system has already received FDA clearance for urologic surgical procedures, and Medtronic has now submitted new 510(k) filings seeking expanded approval for its use in general surgery and gynecological procedures.
Dexcom CEO Jake Leach believes the findings could help establish CGM as a standard of care for type 2 diabetes patients who are not on insulin.
In addition to weight loss, women taking Foundayo also experienced notable reductions in waist circumference, suggesting reduced abdominal fat and cardiometabolic risk, according to Eli Lilly.
Retia Medical expands partnership with Medtronic to distribute its hemodynamic system, Argos Cardiac Output Monitor, in Western Europe.
Unlike conventional immune support products that focus mainly on seasonal wellness, SynbioTech’s newly launched probiotic is designed to support healthy immune ageing.
Novo Nordisk plans to begin a phase 3 development programme for zenagamtide in adults with type 2 diabetes during the second half of 2026.
Let’s explore how robotic surgery is evolving in India with Dr. Sudhir Srivastava, Chairman and CEO of SS Innovations.
The acquisition strengthens Photocure’s bladder cancer diagnostics portfolio by adding Vesica Health’s urine-based molecular diagnostic technology – AssureMDx.